Phio Pharmaceuticals Corp. - PHIO STOCK NEWS

Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), headquartered in Marlborough, Massachusetts, is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company's proprietary INTASYL™ siRNA gene silencing technology is at the forefront of its efforts to enhance the effectiveness of immune cells in targeting and destroying tumor cells.

Phio's core product pipeline includes:

PH-762: Targets the checkpoint protein PD-1 on immune cells, enhancing their ability to attack tumors. Currently in Phase 1b clinical trials, PH-762 is being tested for its efficacy in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
PH-804: Focuses on the suppressive immune receptor TIGIT, present on T cells and natural killer cells, to bolster immune responses against cancer.
PH-790: Aims to silence the PD-L1 protein, which normally prevents immune cells from attacking non-harmful cells, thereby boosting the body's natural defenses against cancer.

Phio Pharmaceuticals collaborates with leading institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München to advance their research and development efforts. The company's financial health, as of the latest reports, shows a cash position of $6.5 million, with a significant reduction in research and development expenses aimed at transitioning from discovery to product development.

Phio's latest updates include the presentation of new data on PH-762 at various scientific conferences and the initiation of new partnerships. These efforts underscore Phio's commitment to delivering cutting-edge cancer treatments and improving patient outcomes.

For more details, visit the company's website at www.phiopharma.com.

10/12/2023 11:00 AM

News

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Rhea-AI Summary

Phio Pharmaceuticals to present new preclinical data at SITC Annual Meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-32.31%

Tags

10/11/2023 07:30 AM

News

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

Rhea-AI Summary

Phio Pharmaceuticals presents preclinical data on INTASYL compound PH-894 at AACR-NCI-EORTC Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

87.05%

Tags

09/06/2023 07:30 AM

News

Phio CEO to Speak at Wainwright Conference in New York in September

Rhea-AI Summary

Phio Pharmaceuticals CEO to present at H.C. Wainwright Conference, discussing FDA IND approvals for lead product PH-762 and new leadership team

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.43%

Tags

08/21/2023 07:30 AM

News

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

Rhea-AI Summary

Phio Pharmaceuticals announces first patient dosed in Adoptive Cell Therapy trial for metastatic melanoma and solid tumors

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.39%

Tags

08/10/2023 04:30 PM

News

Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

Phio Pharmaceuticals reports Q2 2023 financial results and provides business update

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.75%

Tags

06/02/2023 01:30 PM

News

Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.18%

Tags

05/31/2023 08:00 AM

News

Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-13.15%

Tags

05/24/2023 07:30 AM

News

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.3%

Tags

05/18/2023 12:00 PM

News

Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

Rhea-AI Summary

Phio Pharmaceuticals presents pre-clinical data demonstrating the potential of its INTASYL platform to enhance anti-tumor response in NK cells, creating a more effective cell therapy for cancer treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

34.31%

Tags

05/16/2023 07:30 AM

News

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Rhea-AI Summary

Phio Pharmaceuticals has received FDA clearance to proceed with a clinical trial of its lead product candidate, PH-762. The trial will evaluate the safety and efficacy of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell. Phio plans to initiate the trial in the second half of 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

21.36%

Tags

FAQ

What is the current stock price of Phio Pharmaceuticals (PHIO)?

The current stock price of Phio Pharmaceuticals (PHIO) is $2.2 as of December 24, 2024.

What is the market cap of Phio Pharmaceuticals (PHIO)?

The market cap of Phio Pharmaceuticals (PHIO) is approximately 2.3M.

What does Phio Pharmaceuticals Corp. do?

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics to enhance the effectiveness of immune cells in killing tumor cells using its proprietary INTASYL™ siRNA gene silencing technology.

What is INTASYL™ technology?

INTASYL™ is Phio Pharmaceuticals' proprietary self-delivering RNAi technology designed to target specific proteins that inhibit the body's immune response against cancer, without the need for specialized formulations or delivery systems.

What are Phio's key products?

Phio's key products include PH-762, targeting PD-1; PH-804, targeting TIGIT; and PH-790, targeting PD-L1, all aimed at boosting the immune system’s ability to combat cancer.

Who are Phio's collaboration partners?

Phio collaborates with notable institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München.

What recent achievements has Phio Pharmaceuticals announced?

Recent achievements include the presentation of new data on PH-762, progress in clinical trials, and new partnerships aimed at advancing their immuno-oncology programs.

What is the financial condition of Phio Pharmaceuticals?

As of the latest reports, Phio Pharmaceuticals has a cash position of $6.5 million. The company has reduced research and development expenses to focus on transitioning from discovery to product development.

What is PH-762?

PH-762 is an INTASYL compound that targets the PD-1 protein on immune cells, enhancing their ability to attack cancer cells. It is currently in Phase 1b clinical trials.

What cancers is PH-762 being tested for?

PH-762 is being tested for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma in its Phase 1b clinical trials.

What is the significance of INTASYL™ technology?

INTASYL™ technology is significant because it allows for precise targeting of proteins that reduce the body's ability to fight cancer, improving the effectiveness of immune cells without the need for specialized drug delivery systems.